{"id":"W3036557825","doi":"10.1002/cncr.33036","title":"Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Ignyta; Sanofi Genzyme; Genentech; Eisai; Leidos; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Astellas Pharma; Gateway for Cancer Research; Celldex Therapeutics; Pfizer; Kite Pharma; Conquer Cancer Foundation","keywords":"Medicine; HRAS; Internal medicine; Cancer; Prospective cohort study; Oncology; Confidence interval; Salivary gland cancer; Cohort; Gastroenterology; Surgery; Colorectal cancer; KRAS","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005566012,0.0001883857,0.0004111197,0.00005758714,0.00003097923,0.0000140699,0.0000664398,0.00003539784,0.002120559],"category_scores_gemma":[0.00004145064,0.0001394097,0.00008741254,0.0003048542,0.00003269748,0.00005626375,0.00002877355,0.0001732633,0.00007628873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001846677,"about_ca_system_score_gemma":0.0002028659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008101808,"about_ca_topic_score_gemma":0.0003360985,"domain_scores_codex":[0.9988764,0.00003870913,0.0002571183,0.0003439145,0.000204142,0.0002797376],"domain_scores_gemma":[0.9994322,0.00005677438,0.0000681183,0.0001581492,0.000038367,0.0002463677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000371612,0.0003042754,0.9764138,0.0002035186,0.0002208664,0.0006679657,0.0008062037,0.00004736346,0.0002330686,0.0001111994,0.008410186,0.0122099],"study_design_scores_gemma":[0.009403766,0.000723183,0.9175258,0.0008908358,0.0006654611,0.00004545287,0.0001884901,0.001017371,0.004973076,0.0001523977,0.06397524,0.0004389644],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9678912,0.01878967,0.000009650415,0.01066206,0.0003859501,0.0004981862,0.0001392812,0.00005703741,0.001567004],"genre_scores_gemma":[0.9900582,0.004834032,0.00009866364,0.004058836,0.0003664396,0.0003940065,0.00004726097,0.00002974691,0.0001127613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05888808,"threshold_uncertainty_score":0.9987916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07151105991652265,"score_gpt":0.3514154203827536,"score_spread":0.2799043604662309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}